Psoriasis is a common, chronic, immune-mediated disease manifested in the skin, affecting 2-3% of the population. It appears in early adulthood and is a lifelong condition. Up to 90% of all psoriasis patients have plaque psoriasis, which is characterized by “plaques” of the skin, that are mainly found on the scalp, knees, elbows, trunk, and limbs causing itching and pain. Psoriasis is diagnosed by medical examination and can upon diagnosis be treated accordingly. The first in line treatments include topical corticosteroids, while severe cases may receive biologics and oral treatments.

There is a need for biomarkers in psoriasis to improve diagnosis, determine disease severity, predict psoriasis development, and track therapeutic response. All of this will lead to improvement of patient management and reduce clinical trial size and length when developing new efficacious treatments.

Psoriasis is characterized as a dermatological disease where the tissue architecture is being remodeled. The main component of the skin is collagens, which are remodeled as a part of normal homeostasis of the skin. In psoriasis, there is an imbalance of tissue build up and tissue break down, resulting in a net degradation of the tissue. Protein fingerprint biomarkers can quantify skin tissue turnover directly in a serum sample and serve as a liquid biopsy.

Please don't hesitate to contact us if you have any questions or other inquiries.

Please don't hesitate to contact us if you have any questions or other inquiries.

Are you interested in learning more about Nordic Bioscience?
Enter your information in the form and a representative will contact you shortly.

By submitting this form you agree to our terms and conditions.

We use cookies on our site to enable essential services and functionalities, and collect data in regards to visitor information to provide the best possible experience. By using our website, you agree to our Privacy Policy and our cookies usage. Cookie Policy Privacy Statement